Moberg Pharma AB (OSTO:MOB) 3-Year EBITDA Growth Rate : 53.60% (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Moberg Pharma AB 3-Year EBITDA Growth Rate?

Moberg Pharma AB's EBITDA per Share for the three months ended in Mar. 2024 was kr-0.15.

During the past 3 years, the average EBITDA Per Share Growth Rate was 53.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Moberg Pharma AB was 62.90% per year. The lowest was -67.20% per year. And the median was 41.30% per year.

Competitive Comparison of Moberg Pharma AB's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moberg Pharma AB's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Moberg Pharma AB's 3-Year EBITDA Growth Rate falls into.

Moberg Pharma AB 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Moberg Pharma AB (OSTO:MOB) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Moberg Pharma AB 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Moberg Pharma AB's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Moberg Pharma AB (OSTO:MOB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Moberg Pharma AB (OSTO:MOB) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

MB8:Germany

Address

Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51

Website

https://www.mobergpharma.se

Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Moberg Pharma has commercial agreements with partners in Europe and Canada, among others.